that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).
The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than October 16, 2013.
A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198-0001:
1. Glory Burns, Fort Collins, Colorado, Robin Isham, Templeton, California, Andrea Voss, Chadron, Nebraska, Julie Jennings, Lone Tree, Colorado, and R. Will Isham, Gordon, Nebraska, individually Thrombosis, and Vascular Biology 28:2209 -2215 , 2008 (hereafter the ''ATVB paper'').
• Aggarwal, N.T., Pfister, S.L., Gauthier, K.M., Chawengsub, Y., Baker, J.E., & Campbell, W.B. ''Chronic hypoxia enhances 15-lipoxygenase-mediated vasorelaxation in rabbit arteries.'' American Journal of Physiology-Heart Circulation Physiology 296:H678-H688, 2008 (hereafter the ''AJP paper'').
• Aggarwal, N.T., Principal Investigator (P.I.), National Scientist Development grant application to the American Heart Association No. 11SDG7650072, ''Sulfonylurea rReceptor-2 splice variant and mitochondrial mechanisms for cardioprotection and arrhythmia'' (hereafter the ''AHA grant application'').
• K99 HL113518-01, ''Mitochondrial ATP-sensitive K-channels and pharmacological approaches for cardioprotection,'' Aggarwal, Nitin, Ph.D., P.I.
• Specifically, ORI found that Respondent engaged in research misconduct by falsifying Western blot loading control data by inverting, duplicating, and cropping source blot films and/or using films from unrelated experiments to construct five (5) false Western blot figures. In the absence of valid blot images, Respondent falsified and/or fabricated the corresponding quantitative data for summary bar graphs and the data statistics in related text. Respondent admitted to falsely reporting the number of mice reported for an experiment reported in Figure 4 in grant application HL113518-01 to support the hypothesis of the research. The falsified and/or fabricated data are:
• False +-actin data and statistics in Figures 1A and 1B in the AJP paper and Figures 41A and 41B in the thesis (p. 131) that purport to represent a timecourse of 15-LO-1 protein expression in rabbit aortic endothelial cells (RAECs) following hypoxia.
• false +-actin and 15-LO-1 data and statistics in Figures 2A and 2B in the AJP paper and Figures 45A and 45B in the thesis (p. 135) that purport to represent 15-LO-1 expression in aortic rings of normoxic and hypoxic rabbits.
• false +-actin data and statistics in Figures 3A and 3B • false +-actin data and statistics in Figures 1A and 1B in the ATVB paper and Figures 26A and 26B in the thesis (p. 105) that purport to demonstrate changes in 15-LO-1 expression in different arteries of cholesterol-animals; the false +-actin data in Figure 1A , ATVB was the same image as that used for Figure 1A , AJP but flipped vertically.
• false GAPDH data and statistics in Figure 7 in the AHA grant application that purport to represent SUR2A-55 expression in murine heart following left ventricular hypertrophy (LVH).
• false reporting in Figure 4A of grant application HL113518-01 for the number of mice used for the physiological data for ATP-induced potassium influx in murine mitochondria as three to four, when only a single mouse was studied.
Dr. Aggarwal has entered into a Voluntary Settlement Agreement and has voluntarily agreed for a period of three (3) years, beginning on September 17, 2013:
(1) To have his research supervised; Respondent agreed that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which his participation is proposed and prior to his participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of his duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of his research contribution; he agreed that he shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan;
(2) that any institution employing him shall submit in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHSsupported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived, and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and (3) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. • Mail: NIOSH Docket Office, Robert A. Taft Laboratories, MS-C34, 4676 Columbia Parkway, Cincinnati, OH 45226.
All information received in response to this notice and meeting must include the agency name and docket number (CDC-2013-0015; NIOSH-237-A 
